Geron (GERN) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.
The company said the committee considered the data from a phase 3 clinical trial, where Rytelo reduced patients' need for red blood cell transfusions in the first 24 weeks of treatment, compared with placebo.
Geron said the European Commission is set to review the committee's recommendation and is expected to issue its final decision on the marketing authorization application in the coming months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.